ABSTRACT
Liposomal amphotericin B (L-Amp B), a novel formulation of amphotericin B, is effective
for the treatment of invasive fungal infections in children and adults and is associated
with less toxicity than the conventional preparation. Data on the use of Liposomal
amphotericin B in neonates is scarce. We describe the clinical course of two premature
infants who were treated with Liposomal amphotericin B (one infant had candidemia,
and the other had candidemia and meningitis), and provide a summary of previously
published experience on this topic. Liposomal amphotericin B may be an option for
therapy of invasive candidiasis in neonates who are at high risk of nephro-toxicity
and other amphotericin-related reactions, but clinical trials are necessary to document
its safety and efficacy in this age group.
Keywords
Liposomal Amphotericin - neonate - candidiasis - meningitis
